Strategies of microspheres and <i>in situ</i> forming gel implants in long-acting and research progress in controlling burst release

XIAO Limeng; YAN Zhen; YIN Lifang

doi:10.11665/j.issn.1000-5048.20220102

Journal of China Pharmaceutical University > 2022 > 53(1): 10-17. > DOI: 10.11665/j.issn.1000-5048.20220102

XIAO Limeng, YAN Zhen, YIN Lifang. Strategies of microspheres and in situ forming gel implants in long-acting and research progress in controlling burst release[J]. Journal of China Pharmaceutical University, 2022, 53(1): 10-17. DOI: 10.11665/j.issn.1000-5048.20220102

Citation:

PDF (1974 KB)

Strategies of microspheres and in situ forming gel implants in long-acting and research progress in controlling burst release

1.
Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009
2.
Engineering Ｒesearch Center for Development and Evaluation of Sustained-Ｒelease Intelligent Preparations and Key Functional Excipients of Jiangsu Province, Nanjing 210009, China

Funds: This study was supported by the Key Discipline Project of Jiangsu (III)— The Disruptive Theory and Technology Innovative Research Team Project

More Information

Received Date: July 01, 2021
Revised Date: January 06, 2022

Graphical Abstract

Abstract

Abstract

Long-acting injectables(LAIs) play an important role in the field of drug preparation research because they can control drug release for a long time and decrease dosing frequency. In this review, two types of LAIs, including injectable microspheres and in situ forming gel implants, were used as the breakthrough point to analyze the strategies and technologies used in the formulation and process to achieve long-acting drug release.At the same time, in view of the common burst release phenomenon, the relevant coping strategies in the current research were summarized, which provides some reference for the design, development and optimization of such long-acting preparations.
- microspheres,
- in situ forming gel implant,
- long-acting,
- burst release,
- advances

FullText(HTML)

References (52)

References

[1]	. Drug Discov Today，2020，25（2）：321-329.
[2]	Wan F，Yang M. Design of PLGA-based depot delivery systems for biopharmaceuticals prepared by spray drying［J］. Int J Pharm，2016，498（1/2）：82-95.
[3]	Li GQ，Wu DD，Man YQ，et al. Research progress of polypeptides transdermal delivery［J］. Chin J Hosp Pharm（中国医院药学杂志），2018，38 （19）：2084-2087.
[4]	Asfour MH. Advanced trends in protein and peptide drug delivery：a special emphasis on aquasomes and microneedles techniques［J］. Drug Deliv Transl Res，2021，11（1）：1-23.
[5]	Rodrigues de Azevedo C，von Stosch M，Costa MS，et al. Modeling of the burst release from PLGA micro-and nanoparticles as function of physicochemical parameters and formulation characteristics［J］. Int J Pharm，2017，532（1）：229-240.
[6]	Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia：part 4（中华人民共和国药典：四部）［S］. Beijing：China Medical Science Press，2020：474.
[7]	Abadi SS，Moin A，Veerabhadrappa GH. Review article：fabricated microparticles：an innovative method to minimize the side effects of NSAIDs in arthritis［J］. Crit Rev Ther Drug Carrier Syst，2016，33（5）：433-488.
[8]	Hamoudi-Ben Yelles MC，Tran Tan V，Danede F，et al. PLGA implants：How Poloxamer/PEO addition slows down or accelerates polymer degradation and drug release［J］. J Control Release，2017，253：19-29.
[9]	Martín-Sabroso C，Fraguas-Sánchez AI，Aparicio-Blanco J，et al. Critical attributes of formulation and of elaboration process of PLGA-protein microparticles［J］. Int J Pharm，2015，480（1/2）：27-36.
[10]	Tamani F，Bassand C，Hamoudi MC，et al. Mechanistic explanation of the （up to） 3 release phases of PLGA microparticles：diprophylline dispersions［J］. Int J Pharm，2019，572：118819.
[11]	Gasmi H，Siepmann F，Hamoudi MC，et al. Towards a better understanding of the different release phases from PLGA microparticles：dexamethasone-loaded systems［J］. Int J Pharm，2016，514（1）：189-199.
[12]	Fonseca-Santos B，Chorilli M. An overview of carboxymethyl derivatives of chitosan：their use as biomaterials and drug delivery systems［J］. Mater Sci Eng C Mater Biol Appl，2017，77：1349-1362.
[13]	Uyen NTT，Hamid ZAA，Tram NXT，et al. Fabrication of alginate microspheres for drug delivery：a review［J］. Int J Biol Macromol，2020，153：1035-1046.
[14]	Molavi F，Barzegar-Jalali M，Hamishehkar H. Polyester based polymeric nano and microparticles for pharmaceutical purposes：a review on formulation approaches［J］. J Control Release，2020，320：265-282.
[15]	Schoubben A，Ricci M，Giovagnoli S. Meeting the unmet：from traditional to cutting-edge techniques for poly lactide and poly lactide-co-glycolide microparticle manufacturing［J］. J Pharm Investig，2019，49（4）：381-404.
[16]	Benvenutti DF，Bresolin TMB，Corrêa R，et al. A novel stabilizing approach to improve the manufacturing of biodegradable microparticles entrapping plasticizing active molecules：the case of 4-methoxychalcone［J］. J Pharm Innov，2019，14（2）：159-175.
[17]	Zhou J，Hirota K，Ackermann R，et al. Reverse engineering the 1-month Lupron Depot^?［J］. Aaps J，2018，20（6）：105.
[18]	Andhariya JV，Jog R，Shen J，et al. Development of Level A in vitro-in vivo correlations for peptide loaded PLGA microspheres［J］. J Control Release，2019，308：1-13.
[19]	Choi HS，Seo SA，Khang G，et al. Preparation and characterization of fentanyl-loaded PLGA microspheres：in vitro release profiles［J］. Int J Pharm，2002，234（1/2）：195-203.
[20]	Lupron Depot （leuprolide acetate for depot suspension） prescribing information ［EB/OL］.［2021-07-01］. http：//www.lupron.com/prescribing-information.aspx.
[21]	Okada H. One-and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate［J］. Adv Drug Deliv Rev，1997，28（1）：43-70.
[22]	Orsolini P. Pharmaceutical composition in the form of microparticles： US5225205［P］. 1993-07-06.
[23]	PharmaceuticalsVerity，Inc. Trelstar （triptorelin pamoate for injectable suspension） prescribing information［EB/OL］. （2020-05-18）［2021-07-01］. https：//www.trelstar.com/pdf/TrelstarPrescribingInformation_May2020.pdf.
[24]	Skidmore S，Hadar J，Garner J，et al. Complex sameness：separation of mixed poly（lactide-co-glycolide）s based on the lactide：glycolide ratio［J］. J Control Release，2019，300：174-184.
[25]	Lee WY，Asadujjaman M，Jee JP. Long acting injectable formulations：the state of the arts and challenges of poly（lactic-co-glycolic acid） microsphere，hydrogel，organogel and liquid crystal［J］. J Pharm Investig，2019，49（4）：459-476.
[26]	Bisht R，Jaiswal JK，Oliver VF，et al. Preparation and evaluation of PLGA nanoparticle-loaded biodegradable light-responsive injectable implants as a promising platform for intravitreal drug delivery［J］. J Drug Deliv Sci Technol，2017，40：142-156.
[27]	Kempe S，M?der K. In situ forming implants—an attractive formulation principle for parenteral depot formulations［J］. J Control Release，2012，161（2）：668-679.
[28]	Maturavongsadit P，Paravyan G，Kovarova M，et al. A new engineering process of biodegradable polymeric solid implants for ultra-long-acting drug delivery［J］. Int J Pharm X，2021，3：100068.
[29]	Juvekar S，Kathpalia H. Solvent removal precipitation based in situ forming implant for controlled drug delivery in periodontitis［J］. J Control Release，2017，251：75-81.
[30]	Modrzyński JJ，Christensen JH，Brandt KK. Evaluation of dimethyl sulfoxide （DMSO） as a co-solvent for toxicity testing of hydrophobic organic compounds［J］. Ecotoxicology，2019，28（9）：1136-1141.
[31]	Park K，Skidmore S，Hadar J，et al. Injectable，long-acting PLGA formulations：analyzing PLGA and understanding microparticle formation［J］. J Control Release，2019，304：125-134.
[32]	Jain A，Kunduru KR，Basu A，et al. Injectable formulations of poly（lactic acid） and its copolymers in clinical use［J］. Adv Drug Deliv Rev，2016，107：213-227.
[33]	Cox MC，Scripture CD，Figg WD. Leuprolide acetate given by a subcutaneous extended-release injection：less of a pain［J］？Expert Rev Anticancer Ther，2005，5（4）：605-611.
[34]	Suh MS，Kastellorizios M，Tipnis N，et al. Effect of implant formation on drug release kinetics of in situ forming implants［J］. Int J Pharm，2021，592：120105.
[35]	Patel DB. A review on atrigel drug delivery system［J］. J Glob Pharma Technol，2010，2（2）：85-90.
[36]	Wan B，Andhariya JV，Bao Q，et al. Effect of polymer source on in vitro drug release from PLGA microspheres［J］. Int J Pharm，2021，607：120907.
[37]	Bhujel R，Maharjan R，Kim NA，et al. Practical quality attributes of polymeric microparticles with current understanding and future perspectives［J］. J Drug Deliv Sci Technol，2021，64：102608.
[38]	Zhou J，Zhai Y，Xu J，et al. Microfluidic preparation of PLGA composite microspheres with mesoporous silica nanoparticles for finely manipulated drug release［J］. Int J Pharm，2021，593：120173.
[39]	Kamali H，Khodaverdi E，Hadizadeh F，et al. Comparison of in situ forming composite using PLGA-PEG-PLGA with in situ forming implant using PLGA：in-vitro，ex-vivo，and in-vivo evaluation of naltrexone release［J］. J Drug Deliv Sci Technol，2019，50：188-200.
[40]	Mohammadpour F，Kamali H，Hadizadeh F，et al. The PLGA microspheres synthesized by a thermosensitive hydrogel emulsifier for sustained release of risperidone［J］. J Pharm Innov，2021：1-13.
[41]	Yamaguchi Y，Takenaga M，Kitagawa A，et al. Insulin-loaded biodegradable PLGA microcapsules：initial burst release controlled by hydrophilic additives［J］. J Control Release，2002，81（3）：235-249.
[42]	Bode C，Kranz H，Kruszka A，et al. In-situ forming PLGA implants：how additives affect swelling and drug release［J］. J Drug Deliv Sci Technol，2019，53：101180.
[43]	Wang A，Liang R，Liu W，et al. Effect of palmitic acid on the characteristics and release profiles of rotigotine-loaded microspheres［J］. Pharm Dev Technol，2016，21（1）：3-7.
[44]	Liu JW，Ren H，Xu Y，et al. Mechanistic evaluation of the opposite effects on initial burst induced by two similar hydrophilic additives from octreotide acetate-loaded PLGA microspheres［J］. J Pharm Sci，2019，108（7）：2367-2376.
[45]	Xu J，Bai Y，Li X，et al. Porous core/dense shell PLA microspheres embedded with high drug loading of bupivacaine crystals for injectable prolonged release［J］. AAPS PharmSciTech，2021，22（1）：27.
[46]	Zhang WJ，Ning C，Xu WG，et al. Precision-guided long-acting analgesia by hydrogel-immobilized bupivacaine-loaded microsphere［J］. Theranostics，2018，8（12）：3331-3347.
[47]	Liu J，Xu Y，Liu Z，et al. A modified hydrophobic ion-pairing complex strategy for long-term peptide delivery with high drug encapsulation and reduced burst release from PLGA microspheres［J］. Eur J Pharm Biopharm，2019，144：217-229.
[48]	Thedrattanawong C，Manaspon C，Nasongkla N. Controlling the burst release of doxorubicin from polymeric depots via adjusting hydrophobic/hydrophilic properties［J］. J Drug Deliv Sci Technol，2018，46：446-451.
[49]	Chen LQ，Ahmed AMQ，Deng YB，et al. Novel triptorelin acetate-loaded microspheres prepared by a liquid/oil/oil method with high encapsulation efficiency and low initial burst release［J］. J Drug Deliv Sci Technol，2019，54：101390.
[50]	Dong N，Zhu C，Jiang J，et al. Development of composite PLGA microspheres containing exenatide-encapsulated lecithin nanoparticles for sustained drug release［J］. Asian J Pharm Sci，2020，15（3）：347-355.
[51]	Zhang Y，Fei S，Yu M，et al. Injectable sustained release PLA microparticles prepared by solvent evaporation-media milling technology［J］. Drug Dev Ind Pharm，2018，44（10）：1591-1597.
[52]	Deng XQ，Liu YJ，Qin JX，et al. A novel pellets/thermosensitive hydrogel depot with low burst release for long-term continuous drug release：preparation，characterization，in vitro and in vivo studies［J］. J Drug Deliv Sci Technol，2020，60：102050.

Cited By

Get Citation

PDF

XML

Article views (484) PDF downloads (975)

Turn off MathJax

Article Contents

Abstract

References

Strategies of microspheres and in situ forming gel implants in long-acting and research progress in controlling burst release

Abstract

References

Catalog

Export File

Citation

Format

Content